Related Experiment Video
Updated: Aug 21, 2026
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Pneumococcal conjugate vaccines--a European perspective
1Institute for Medical Microbiology, National Reference Centre for Streptococci, University Hospital, Pauwelsstrasse 30, D-52057 Aachen, Germany. Reinert@rwth-aachen.de
Insights
Pneumococcal conjugate vaccines significantly reduce invasive pneumococcal disease in children. Further research is needed on vaccine effectiveness in diverse populations and broader serotype coverage.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Streptococcus pneumoniae causes severe childhood illnesses like pneumonia and meningitis globally.
- High incidence and mortality rates in young children underscore the need for effective interventions.
- Increasing antibiotic resistance in Europe highlights the urgency for novel control strategies.
Purpose of the Study:
- To evaluate the impact and effectiveness of the 7-valent pneumococcal conjugate vaccine (7vPCV) in European children.
- To address key questions regarding vaccine efficacy in high-risk groups, serotype replacement, and otitis media prevention.
- To discuss the role of pneumococcal vaccination in controlling disease and antibiotic resistance across Europe.
Main Methods:
- Review of existing data on pneumococcal disease incidence and antibiotic resistance patterns in Europe.
- Analysis of the introduction and expected impact of the 7-valent pneumococcal conjugate vaccine (7vPCV).
- Discussion of ongoing research and future directions in pneumococcal vaccine development.
Main Results:
- The 7-valent pneumococcal conjugate vaccine (7vPCV) shows high efficacy in preventing invasive pneumococcal disease in infants.
- Significant reductions in invasive pneumococcal disease incidence and antibiotic resistance are anticipated with widespread vaccine use.
- Varied vaccine recommendations and uptake exist across European countries, with France and Spain leading in guidelines.
Conclusions:
- Pneumococcal conjugate vaccines represent a major advancement in controlling pneumococcal diseases in European children.
- Further development of multi-valent vaccines (e.g., 9-valent, 11-valent) is crucial for broader serotype coverage and enhanced protection.
- Continued monitoring of vaccine effectiveness, serotype replacement, and co-administration strategies is essential for optimizing public health outcomes.
Abstract:
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and acute otitis media in children and adults worldwide. In the age group of < 2 years the incidence of invasive pneumococcal disease ranges from approximately 14 cases per 100,000 in Germany and the Netherlands and more than 90 per 100,000 children in Spain. The vulnerability of children to S. pneumoniae can also be demonstrated by the high rate of sequelae (> 20% in Germany) and the high mortality (7.5%) in pneumococcal meningitis. Furthermore, antibiotic resistance of S. pneumoniae is increasing in Europe, particularly in France, Spain, and Eastern European countries, whereas Germany and Northern Europe are only marginally affected. A 7-valent pneumococcal conjugate vaccine (7vPCV) that was shown to be highly efficacious in preventing invasive pneumococcal disease in infants in the USA was licensed in Europe in 2001. It is expected that broad usage of the vaccine would reduce the incidence of invasive pneumococcal disease and the levels of pneumococcal resistance significantly. Important questions have been raised regarding the effectiveness of this vaccine in high-risk populations, serotype replacement, the efficacy of this vaccine in otitis media, and the co-administration of the new vaccine with other standard childhood vaccines used in various European countries. France and Spain currently have the most-wide ranging guidelines recommending pneumococcal vaccination for children. Overall, the development of pneumococcal conjugate vaccines is a significant step in the control of pneumococcal disease in children in Europe. Further progress in pneumococcal vaccine development can be expected from conjugate vaccines including more than seven serotypes (9-valent, 11-valent).
Related Concept Videos
01:27Streptococcal Pharyngitis
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
01:21Vaccines